Summary
Fifteen patients with recurrent squamous cell head and neck cancer were treated with deoxyspergualin. There were no objective responses in 14 evaluable patients. The most common toxicity was reversible hypotension, which prompted dose reduction in nine patients. Deoxyspergualin is not recommended for the treatment of squamous cell head and neck cancer.
Similar content being viewed by others
References
Urba SG, Forastiere AA: Systemic therapy of head and neck cancer: most effective agents, areas of promise. Oncol 3(4):79–88, 1989
Takeuchi T, Iinuma H, Kunimoto S, Masuda T, Ishizuka M, Takeuchi M, Hamada M, Naganawa H, Kondo S, Umezawa H: A new antitumor antibiotic spergualin: isolation and antitumor activity. J Antibiot (Tokyo), 34:1619–1621, 1981
Deoxyspergualin (NSC 356894). National Cancer Institute. Clinical Brochure, June 1990
Muindi JF, Lee S-J, Baltzer L, Jakubowski A, Scher H, Sprancmania LA, Riley CH, Vander Velde D, Young C: Clinical pharmacology of deoxyspergualin in patients with advanced cancer. Cancer Res 51:3096–3101, 1991
Havlin K, Koeller J: Personal communication.
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Pai LH, FitzGerald DJ, Tepper M, Schacter B, Spitalny G, Pastan I: Inhibition of antibody response to pseudomonas exotoxin and an immunotoxin containing pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res 50: 7750–7753, 1990
Author information
Authors and Affiliations
Additional information
Drs. Pfister and Motzer are recipients of an American Cancer Society Clinical Oncology Career Development Award.
Rights and permissions
About this article
Cite this article
Pfister, D.G., Bajorin, D., Motzer, R.J. et al. A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer. Invest New Drugs 11, 53–56 (1993). https://doi.org/10.1007/BF00873911
Issue Date:
DOI: https://doi.org/10.1007/BF00873911